TY - JOUR
T1 - Erratum
T2 - Childhood asthma in the new omics era: challenges and perspectives: Erratum (Current opinion in allergy and clinical immunology (2020) 20 2 (155-161))
AU - PERMEABLE consortium
AU - Golebski, Korneliusz
AU - Kabesch, Michael
AU - Melén, Erik
AU - Potočnik, Uroš
AU - van Drunen, Cornelis M
AU - Reinartz, Susanne
AU - Maitland-van der Zee, Anke H
AU - Vijverberg, Susanne J H
N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2020/8/1
Y1 - 2020/8/1
N2 - PURPOSE OF REVIEW: Childhood asthma is a heterogeneous inflammatory disease comprising different phenotypes and endotypes and, particularly in its severe forms, has a large impact on the quality-of-life of patients and caregivers. The application of advanced omics technologies provides useful insights into underlying asthma endotypes and may provide potential clinical biomarkers to guide treatment and move towards a precision medicine approach.RECENT FINDINGS: The current article addresses how novel omics approaches have shaped our current understanding of childhood asthma and highlights recent findings from (pharmaco)genomics, epigenomics, transcriptomics, and metabolomics studies on childhood asthma and their potential clinical implications to guide treatment in severe asthmatics.SUMMARY: Until now, omics studies have largely expanded our view on asthma heterogeneity, helped understand cellular processes underlying asthma, and brought us closer towards identifying (bio)markers that will allow the prediction of treatment responsiveness and disease progression. There is a clinical need for biomarkers that will guide treatment at the individual level, particularly in the field of biologicals. The integration of multiomics data together with clinical data could be the next promising step towards development individual risk prediction models to guide treatment. However, this requires large-scale collaboration in a multidisciplinary setting.
AB - PURPOSE OF REVIEW: Childhood asthma is a heterogeneous inflammatory disease comprising different phenotypes and endotypes and, particularly in its severe forms, has a large impact on the quality-of-life of patients and caregivers. The application of advanced omics technologies provides useful insights into underlying asthma endotypes and may provide potential clinical biomarkers to guide treatment and move towards a precision medicine approach.RECENT FINDINGS: The current article addresses how novel omics approaches have shaped our current understanding of childhood asthma and highlights recent findings from (pharmaco)genomics, epigenomics, transcriptomics, and metabolomics studies on childhood asthma and their potential clinical implications to guide treatment in severe asthmatics.SUMMARY: Until now, omics studies have largely expanded our view on asthma heterogeneity, helped understand cellular processes underlying asthma, and brought us closer towards identifying (bio)markers that will allow the prediction of treatment responsiveness and disease progression. There is a clinical need for biomarkers that will guide treatment at the individual level, particularly in the field of biologicals. The integration of multiomics data together with clinical data could be the next promising step towards development individual risk prediction models to guide treatment. However, this requires large-scale collaboration in a multidisciplinary setting.
UR - http://www.scopus.com/inward/record.url?scp=85087320593&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/ACI.0000000000000662
DO - https://doi.org/10.1097/ACI.0000000000000662
M3 - Comment/Letter to the editor
C2 - 31985545
SN - 1528-4050
VL - 20
SP - 428
JO - Current opinion in allergy and clinical immunology
JF - Current opinion in allergy and clinical immunology
IS - 4
ER -